Medical Health & Life Science Research News

New report shares details about the midkine pipeline review, H1 2017

New report shares details about the midkine pipeline review, H1 2017

HTF Market Intelligence released a new research report of 42 pages on title 'Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Pipeline Review, H1 2017' with detailed analysis, forecast and strategies. The study covers key regions and important players such as Cellmid Ltd, Ribomic Inc

- Advertisement -
- Membership expired -

Summary
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Pipeline Review, H1 2017

According to the recently published report 'Midkine - Pipeline Review, H1 2017'; Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.

Request a sample report @ www.htfmarketreport.com/sample-rep…-pipeline-review 

Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Midkine (MDK) or neurite growth-promoting factor 2 is a protein encoded by the MDK gene. It binds to anaplastic lymphoma kinase which induces ALK activation and subsequent phosphorylation of the insulin receptor substrate, activation of mitogen-activated protein kinase and PI3-kinase and the induction of cell proliferation.

- Advertisement -
- Membership expired -
It is involved in neointima formation after arterial injury and early fetal adrenal gland development.

The report 'Midkine - Pipeline Review, H1 2017' outlays comprehensive information on the Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviewsalso reviews key players involved in Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical stages are 7 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Genito Urinary System And Sex Hormones, Immunology, Gastrointestinal, Metabolic Disorders, Musculoskeletal Disorders, Cardiovascular and Respiratory which include indications Inflammation, Kidney Fibrosis, Liver Fibrosis, Non-Small Cell Lung Cancer, Acute Renal Failure (ARF) (Acute Kidney Injury), Autoimmune Disorders, Bone Disorders, Bone Fracture, Chronic Kidney Disease (Chronic Renal Failure), Diabetic Nephropathy, Kidney Disease, Lung Disease, Neuroblastoma, Osteoporosis, Prostate Cancer and Squamous Non-Small Cell Lung Cancer.

Scope

- The report provides a snapshot of the global therapeutic landscape for Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK)
- The report reviews Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics and enlists all their major and minor projects
- The report assesses Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics

Reasons to access

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

Companies Mentioned in the Report

Cellmid Ltd
Ribomic Inc

Enquire Now @ www.htfmarketreport.com/request-di…-pipeline-review

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Overview
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth


....Continued

View Detailed Table of Content @ www.htfmarketreport.com/reports/49…k-pipeline-review


Access this report @ www.htfmarketreport.com/buy-now?fo…amp;report=498320

News From

HTF Market Intelligence ConsultingHTF Market Intelligence...
Category: Market Research Publishers and RetailersCompany profile: HTF Market Report is wholly owned brand of HTF market Intelligence Consulting Private Limited which provides next-generation service for organizations with a deep focus on market intelligence, data analytics, and social intelligence, all uniquely delivered under one roof by skilled professionals. By combining and analyzing acquire lucid and most relevant data which would help in better decision-making. We provide your requirements with speed and cost benefit across the world, we are able to achi ...

For more information:

Make an Inquiry about this report HERE!
  • www.htfmarketreport.com
  • www.htfmarketreport.com/sample-rep…k-pipeline-review
  • www.htfmarketreport.com/request-di…k-pipeline-review
  • www.htfmarketreport.com/reports/49…k-pipeline-review
  • www.htfmarketreport.com/buy-now?fo…amp;report=498320